Probiotic for Alleviating Functional Constipation in Adults
Weizmannia Coagulans BC99 Improved Intestinal Motility and Chronic Constipation Through Regulating Gut Microbiota: a Randomized, Double-blind, Placebo-controlled Trial
1 other identifier
interventional
100
1 country
1
Brief Summary
To investigate the clinical effects of probiotics in relieving chronic constipation in adults, and evaluate the improvement of symptoms in patients with constipation as well as their impacts on gastrointestinal function and gut microbiota.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2024
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 2, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 9, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
October 4, 2024
CompletedFirst Submitted
Initial submission to the registry
June 10, 2026
CompletedFirst Posted
Study publicly available on registry
June 16, 2026
CompletedJune 16, 2026
June 1, 2026
1 month
June 10, 2026
June 10, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
1. Assessing the Improvement of Chronic Constipation Symptoms Following Probiotic Intervention.
Constipation symptoms are measured using Bristol Stool Form Scale, which classifies stool into seven types (1-2 indicate constipation, 3-4 normal, and 5-7 diarrhea) for self-assessment or clinical evaluation of bowel function.
8 weeks
Study Arms (2)
Probiotic Group
EXPERIMENTALParticipants receive one sachet per day containing probiotic BC99 and maltodextrin (Week 0 to Week8).
Placebo Group
PLACEBO COMPARATORParticipants receive one sachet per day containing maltodextrin only, serving as the placebo(Week 0 to Week8).
Interventions
During the intervention, participants can consume BC99 daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
During the intervention, participants can consume maltodextrin daily and any adverse reactions were noted. Stool and serum samples were collected for analysis of 16S rRNA and serum inflammatory markers. Changes in intestinal flora and inflammatory factors before and after supplementation were assessed.
Eligibility Criteria
You may qualify if:
- (1) Chinese adults aged 18-70 years who meet the Rome IV diagnostic criteria for chronic constipation (duration of at least 6 months, with less than three passing stools per week and/or Bristol Stool Scale types 1 and 2); (2) The patient rarely experiences diarrhea without using laxatives; (3) The criteria for irritable bowel syndrome were insufffcient ; (4) patients that could complete the study according to the requirements of the trial protocol; (5) participants (including male subjects) who have no family planning within 14 days prior to screening and voluntarily take effective contraceptive measures within 6 months after the end of the trial; (6) Patients capable of understanding the clinical study and willing to comply with the study requirements and procedures; (7) Subjects who have signed the informed consent form. Only those who meet all the above conditions can be selected for the study.
You may not qualify if:
- Use of probiotics, prebiotics, or antibiotics within two weeks prior to enrollment and throughout the intervention period;
- Regular use of a high-fiber diet, as measured by the recommended food score (RFS);
- Regular use of medications affecting bowel habits, such as irritable bowel syndrome, functional bloating, and functional diarrhea;
- Currently have, or have had in the past 2 years, any gastrointestinal conditions such as: Crohn's disease, celiac disease, ulcerative colitis, malignant tumor of the colon;
- Medical history of cardiovascular, liver, or renal diseases; alcoholics;
- Hypersensitivity to probiotics or the ingredients used in this study;
- Pregnancy or breastfeeding;
- Participation in another clinical trial in the 3 months before enrollment. -
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The School of Food and Bioengineering, Henan University of Science and Technolog
Luoyang, Henan, 471000, China
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 10, 2026
First Posted
June 16, 2026
Study Start
July 2, 2024
Primary Completion
August 9, 2024
Study Completion
October 4, 2024
Last Updated
June 16, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share